Castle Creek Biosciences, Inc., is a late-stage cell and gene therapy company developing therapies for genetic diseases. Our scientists create optimal therapies that address the distinctive needs of each targeted indication, with an initial focus on skin and connective tissue disorders.
To create transformative therapies that improve lives of people living with genetic diseases.
Castle Creek Biosciences is a portfolio company of Paragon Biosciences.
Paragon is a global life science leader that creates, builds and funds innovative biology-based companies. It accelerates scientific breakthroughs to treat and cure diseases.
People affected by dystrophic epidermolysis bullosa (DEB), a genetic disease that has limited treatment options, inspired us to develop an innovative therapy for this devastating condition.
Tailoring our therapeutic approach for the unique needs of each targeted indication
